Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.62 |
| ▸ | CTSS | P25774 | 3/20 | 0.61 |
| ▸ | CTSK | P43235 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 3/20 | 0.43 |
| ▸ | NOS1 | P29475 | 3/20 | 0.43 |
| ▸ | NOS2 | P35228 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486223 | 1.00 | PSENEN (0.62) | PSENENCTSSCTSKCA2CA1 | |
| SCHEMBL1486221 | 1.00 | PSENEN (0.62) | PSENENCTSSCTSKCA2CA1 | |
| SCHEMBL8835847 | 0.94 | PSENEN (0.71) | PSENENCTSSCTSKCA2CTSD | |
| SCHEMBL23080124 | 0.90 | PSENEN (0.64) | PSENENCTSSCTSKCA2POLB | |
| SCHEMBL9743636 | 0.90 | CTSK (0.61) | PSENENCTSSCTSKCA2CA1 | |
| SCHEMBL22648606 | 0.90 | PSENEN (0.63) | PSENENCTSSCTSKCA2POLB | |
| SCHEMBL22636250 | 0.90 | PSENEN (0.63) | PSENENCTSSCTSKCA2POLB | |
| SCHEMBL22636252 | 0.90 | PSENEN (0.63) | PSENENCTSSCTSKCA2POLB | |
| SCHEMBL8466502 | 0.89 | CTSS (0.59) | PSENENCTSSCTSKCA2CA1 | |
| SCHEMBL8466501 | 0.89 | CTSS (0.59) | PSENENCTSSCTSKCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111562720-B | Photo-sensitized chemically amplified resist material, pattern forming method, semiconductor device, mask for lithography, and template for nanoimprint | 东京毅力科创株式会社 | 2023-09-29 | — | — | CN | disclosed |
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | NAUREX, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20120004309-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | KHAN AMIN (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004309-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | GLS, HGFAC, AADAC | PSENEN 782/4885CTSS 416/4885CTSK 251/4885 |
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | GLS, HGFAC, AADAC | PSENEN 782/4885CTSS 416/4885CTSK 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.